All In Biotech

Drug Trial Radar · NCT05885503

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

A Phase III, Multicenter, Randomized, Double-blind, Active Controlled Trial of RC28-E Intravitreal Injection in Subjects With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Sep 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

316

Planned (sponsor's estimate)

Start

Jun 8, 2023

Primary completion

Jun 2026

Study completion Jun 2026

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.

Conditions

  • Diabetic Macular Edema

Interventions

  • RC-28EBiological

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

  • AfliberceptBiological

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in BCVA at Week 52Time frame: Baseline, week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.